tbuckley/cabot-search huggingface dataset:
LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3
Authors: S. Gillessen, A. Choudhury, F. Saad, E. Gallardo, A. Soares, Y. Loriot, R.S. McDermott, A. Rodriguez-Vida, P. Isaacson, F. Nolè, F.J.S. Melo Cruz, T. Roumeguere, K.G. Daugaard, R. Yamamura, F. Lecouvet, C. Coens, B. Fournier, B. Tombal
Journal: Annals of Oncology (2024)
LBA57 Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12
Authors: F. Barlesi, W. Yao, M. Duruisseaux, L. Doucet, J. Shi, O.J. Juan Vidal, Y-C. Kim, M.R. García Campelo, A. Azkárate Martínez, S. Lu, R. Jotte, E. Felip, G. Lo Russo, M. Reck, Y. Zhang, N. Hu, M.F. Michenzie, T.S.K. Mok
Journal: Annals of Oncology (2024)
LBA8 Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways
Authors: P. Tomasini, C. Cropet, A. Jeanson, M. Pérol, J. Mazieres, C. Fontaine, A. Rabeau, M. Meurer, L. Greillier, M. Le Ray, L. Laborde, A. Cohen, V. Martin, M. Roumieux, F. Monville, E. Vivier, D. Perol, S. Chabaud, F. Barlesi
Journal: Annals of Oncology (2024)
LBA71 Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)
Authors: V. Conteduca, N. Brighi, G. Gurioli, D. Wetterskog, E.F. Giunta, C. Lolli, G. Schepisi, V.E. Chiuri, D. Gasparro, P.A. Zucali, A. Virga, I. Bondi, B. Vertogen, V. Di Iorio, M. Sansovini, S. Severi, E. Scarpi, M. Urbini, G. Attard, U. De Giorgi
Journal: Annals of Oncology (2024)
LBA40 Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
Authors: J. Zhou, J. Fan, S.C. Jiao, L. Bai, J. Luo, Y. Bai, Y. Pan, Y. Gao, R. Shi, W. Zhang, J. Zheng, X. Hua, X. Aibing, S. Hu, M. Da, R. Wang, J. Ma, W. Jia, W. Wu, C. Peng
Journal: Annals of Oncology (2024)
LBA56 Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
Authors: G.J. Riely, M-J. Ahn, J. Clarke, I. Dagogo-Jack, E. Felip, F. Gelsomino, J.W. Goldman, M. Hussein, M.L. Johnson, D. Morgensztern, E. Nadal, M.D. Offin, M. Provencio Pulla, S.S. Ramalingam, E.F. Smit, A.S. Tsao, A. Alcasid, T. Usari, K. Wilner, B. Johnson
Journal: Annals of Oncology (2024)
LBA80 Siremadlin (S) and ribociclib (R) in patients (pt) with advanced well-differentiated/dedifferentiated liposarcomas (WD/DD LPS) and other molecularly selected cancers: Final analysis of the MEGAMOST “Ribociclib/HDM201” basket study
Authors: M. Brahmi, O. Tredan, C.A. Gomez-Roca, A. Italiano, E.B. Saada, F. Bertucci, A. Le Cesne, P. Cassier, I. Treilleux, S. Chabaud, G. Fournier Garin, D. Perol, J-Y. Blay, A. Dufresne
Journal: Annals of Oncology (2024)
LBA83 PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma
Authors: J. Remon Masip, P. Bironzo, N. Girard, L. Bigay-Game, O.J. Juan Vidal, J. de Castro Carpeño, N. Reguart Aransay, L. Greillier, S. Cousin, E. Dansin, M. Majem, R. Bernabe Caro, J. Mosquera Martinez, M. Diaz, A. Meya, D. Alcalá-López, A.G. Sanz, L. Righi, S. Novello, B. Besse
Journal: Annals of Oncology (2024)
LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study
Authors: N. Girard, M. Burotto, L.G. Paz-Ares, M. Reck, M. Schenker, A. Lingua, F.J. Orlandi, J. Naidoo, E.K. Beardlsey, V. Velcheti, G.L. Martinengo, E. Felip, Y. Zhang, P. Kasbekar, M. Chowdhury, T. Spires, A. Tendolkar, M. Cobo Dols
Journal: Annals of Oncology (2024)
LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
Authors: J. Llovet, R.S. Finn, Z. Ren, Y. Guo, G. Han, H. Lin, J. Zheng, S. Ogasawara, H. Li, J.H. Kim, H. Zhao, C. Li, D.C. Madoff, R.M. Ghobrial, A.B. El-Khoueiry, A. Vogel, X. Peng, K. Mody, L. Dubrovsky, M. Kudo
Journal: Annals of Oncology (2024)
LBA43 10-y survival outcomes from the phase III CheckMate 067 trial of nivolumab plus ipilimumab in advanced melanoma
Authors: J. Larkin, V. Chiarion Sileni, C. Gaudy Marqueste, P. Rutkowski, T.M. Medina, C.D. Lao, C.L. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Queirolo, J. Walker, M.O. Butler, A.G. Hill, I. Marquez-Rodas, J.B.A.G. Haanen, A. Nassar, M. Askelson, F.S. Hodi, J.D. Wolchok
Journal: Annals of Oncology (2024)
LBA58 A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTG
Authors: T. Leong, B.M. Smithers, M. Michael, K.M. Haustermans, R. Wong, V. Gebski, R. O'Connell, J.R. Zalcberg, A. Boussioutas, M. Findlay, D. Willis, A. Moore, F. Lordick, C. O'Callaghan, C. Swallow, G.E. Darling, A. Strickland, M. Liberman, L. Mineur, J. Simes
Journal: Annals of Oncology (2024)
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer
Authors: Daniel Morgensztern, Neal Ready, Melissa L. Johnson, Afshin Dowlati, Noura Choudhury, David P. Carbone, Eric Schaefer, Susanne M. Arnold, Sonam Puri, Zofia Piotrowska, Aparna Hegde, Anne C. Chiang, Wade Iams, Anthony Tolcher, Kaname Nosaki, Toshiyuki Kozuki, Tianhong Li, Rafael Santana-Davila, Hiroaki Akamatsu, Haruyasu Murakami, Hiroshi Yokouchi, Song Wang, Jiuhong Zha, Rui Li, Randy R. Robinson, Pooja Hingorani, Edwin E. Jeng, Muhammad Furqan
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, a SEZ6-targeted antibody conjugated to calicheamicin, was evaluated in a phase I study (NCT03639194) in patients with relapsed/refractory SCLC. We report initial outcomes of ABBV-011 monotherapy. Patients and Methods: ABBV-011 was administered intravenously once every 3 weeks during dose escalation (0.3–2 mg/kg) and expansion. Patients with SEZ6-positive tumors (≥25% of tumor cells with ≥1+ staining intensity by IHC) were preselected for expansion. Safety, tolerability, antitumor activity, and pharmacokinetics were evaluated. Results: As of August 2022, 99 patients received ABBV-011 monotherapy [dose escalation, n = 36; Japanese dose evaluation, n = 3; dose expansion, n = 60 (1 mg/kg, n = 40)]; the median age was 63 years (range, 41–79 years). Also, 32%, 41%, and 26% of patients received 1, 2, and ≥3 prior therapies, respectively. The maximum tolerated dose was not reached through 2.0 mg/kg. The most common treatment-emergent adverse events were fatigue (50%), nausea (42%), and thrombocytopenia (41%). The most common hepatic treatment-emergent adverse events were increased aspartate aminotransferase (22%), increased γ-glutamyltransferase (21%), and hyperbilirubinemia (17%); two patients experienced veno-occlusive liver disease. The objective response rate was 19% (19/98). In the 1-mg/kg dose-expansion cohort (n = 40), the objective response rate was 25%; the median response duration was 4.2 months (95% confidence interval, 2.6–6.7); and the median progression-free survival was 3.5 months (95% confidence interval, 1.5–4.2). Conclusions: ABBV-011 1.0 mg/kg every 3 weeks monotherapy was well tolerated and demonstrated encouraging antitumor activity in heavily pretreated patients with relapsed/refractory SCLC. SEZ6 is a promising novel SCLC target and warrants further investigation.
LBA62 Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): Results from the randomized phase II trial PANDAS/PRODIGE 44
Authors: A. Lambert, O. Bouche, A. Ayav, J-B. Bachet, L. Schwarz, G. Piessen, V. Vendrely, V. Laurent, E. Thibaudeau, L. Miglianico, Y. Rinaldi, P. Hammel, T. Conroy
Journal: Annals of Oncology (2024)
1972P Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE
Authors: A. Nizam, L. Zhang, C.Y. Jiang, C.B. Nguyen, D.R. Bakaloudi, M.A. Bilen, P.M. Coelho Barata, Y. Zakharia, M.I. Milowsky, D. Kilari, C.J. Hoimes, A.R. Khaki, H. Emamekhoo, S. Gupta, P. Grivas, J. Bellmunt, A.S. Alva, M.T. Campbell, O. Alhalabi, V.S. Koshkin
Journal: Annals of Oncology (2024)
1929P Dabrafenib and trametinib (D+T) in BRAFV600E differentiated thyroid cancer: A real-world experience in Italy
Authors: L.D. Locati, E. Colombo, L. Fugazzola, P. Bossi, F. Magri, S. Zovato, D. Salvatore, A. Malovini, R. Elisei, C. Durante
Journal: Annals of Oncology (2024)
1973P Urine-based molecular testing identifies FGFR alteration-positive patients for treatment with TAR-210
Authors: F. Guerrero-Ramos, J.H. Ku, A. Vilaseca, C.X. Raventos, N.D. Shore, J. Meeks, R. Li, S. Daneshmand, G. Jayram, T.W. Kang, N. Beeharry, J. Zhang, D. Weingeist, D.A. Smirnov, B. Brunton, C. Cost, A. Kalota, J. Lauring, N. Stone, S. Thomas
Journal: Annals of Oncology (2024)
1990P MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study
Authors: C. Cui, L. Zhou, Y. Yang, W. Qu, X. Sheng, Z. Chi, L. Si, L. Mao, B. Lian, X. Wang, X. Yan, S. Li, C. Li, X. Wei, J. Li, R. Duan, H. Xu, A. Zhou, J. Guo
Journal: Annals of Oncology (2024)
1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
Authors: T.B. Powles, M.S. van der Heijden, S. Gupta, B. Perez Valderrama, M.D. Galsky, J. Bedke, E. Kikuchi, J. Hoffman-Censits, J.P. Maroto Rey, C. Vulsteke, G. Iyer, U. Swami, S.J. Shin, A. Rodriguez-Vida, M. Wozniak, B. Homet Moreno, J. Lu, C. Yu, L. Hogdal, Y. Loriot
Journal: Annals of Oncology (2024)
1878P Efficacy of surgical gloves (SG) as compression therapy to prevent oxaliplatin-induced peripheral neuropathy (PN): The ELEGANT trial
Authors: A. Joureau-Chabert, W. Dronne, Y. Ouldbey, C. Coutzac, E. Chanel, E. Blanc, A. Cattey-Javouhey, S. Evora, A. Barry, V. Montagnier, V. Bourne-Branchu, C. Arbault, C. Siess, K. Vandevoorde, C. de la Fouchardiere
Journal: Annals of Oncology (2024)
1980P Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial
Authors: E. Xylinas, C. Pieczonka, J.M. Jacob, A. Necchi, S. Daneshmand, G. Simone, K. Decaestecker, G. Kulkarni, M. Boegemann, F. Guerrero-Ramos, J. Callaway, N. Beeharry, J. Zhang, S. Hampras, H. Sweiti, K. Stromberg, J. Martin, A. Shukla, P. Raciti, M.S. van der Heijden
Journal: Annals of Oncology (2024)
1986P Prospective evaluation of BCG unresponsive bladder cancer carcinoma in situ identifies genetic mechanisms of immunotherapy resistance and targeted therapy using an ultra-sensitive next generation sequencing minimal residual disease (MRD) assay
Authors: J. Meeks, R. Li, P. Du, C. Carter, S. Kallas, Y. Huang, S. Jia
Journal: Annals of Oncology (2024)
1971P RUTIVAC-1 study: A randomized, double-blind, placebo-controlled phase I trial to evaluate the immunomodulatory effect of RUTI in individuals with high-risk non-muscle-invasive bladder cancer treated with intravesical BCG
Authors: P. Servian, O. Buisan, S. Pedreño-López, J. Pagès, V. Urrea, R. Martinez, E. Garcia, J.J. Areal, M. Amat, C. Cabrera
Journal: Annals of Oncology (2024)
1914P Nintedanib(N) as switch maintenance treatment in malignant pleural mesothelioma (MPM) (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Authors: O.M. Abdel-Rahman, P. Taylor, J. Raskin, C. Dazzi, V. Surmont, R. Young, A.C. Toffart, P. Jankowska, S.I. Marreaud, L. Boone, S. Popat
Journal: Annals of Oncology (2024)
1927P AL2846 in patients (pts) with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) previously treated with tyrosine kinase inhibitors (TKI): Preliminary clinical results from the phase Ib study
Authors: F. Shi, W. Chai, H. Yang, W. Cao, S. Zhang, Z. Chen, W. Ouyang, Y. Cui
Journal: Annals of Oncology (2024)
1917P Updated survival and vaccine response from the NIPU trial: A randomised, phase II study evaluating nivolumab and ipilimumab with or without UV1 vaccination in patients with pleural mesothelioma
Authors: V.D. Haakensen, Å.K. Öjlert, W. Kefi, S.M.H. Thunold, S.J. Farooqi, A.K. Nowak, W.L. Chin, O. Grundberg, W.M. Szejniuk, S.M. Cedres Perez, J.B. Sørensen, T.S. Dalen, M. Lund-Iversen, M.M. Bjaanaes, E.M. Inderberg, A. Helland
Journal: Annals of Oncology (2024)
1943P Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: A joint SITC and INMC effort
Authors: J.S. Deutsch, E. Burton, A. Cimino-Mathews, T.R. Cottrell, C.E. de Andrea, P-O. Fiset, J.E. Gershenwald, G.V. Long, J. Messina, R.F. Salgado, C. Schürch, R. Seethala, L. Sholl, S. Signoretti, M. Tetzlaff, B. van de Wiel, X. Xu, R.A. Scolyer, J. Taube
Journal: Annals of Oncology (2024)
1916P Methylation subtypes correlate with tumor immune contextures and outcome to ICI therapy of pleural mesothelioma (PM) patients: The NIBIT EPI-MESO study
Authors: L. Calabro, F.P. Caruso, A. Covre, M.F. Lofiego, T. Noviello, R. Tufano, V. Lagano, N. Nastasi, G. Sabella, G. Rossi, S. Coral, F. Grosso, L. Cerbone, S. Delfanti, A.M. Di Giacomo, M. Milione, R. Mortarini, A. Anichini, M. Ceccarelli, M. Maio
Journal: Annals of Oncology (2024)
1870P Safety and efficacy of cryotherapy in the prevention and treatment of chemotherapy-induced peripheral neuropathy
Authors: G.V. Giannecchini, R. Brant Costa, A.N. Rodrigues, F.R. Paes, R.C.A. Menezes, F.N.G. Ribeiro, C.P.O. Bessa, M. Sampayo Cordero, L. Mina, B.L. Ferrari
Journal: Annals of Oncology (2024)
1875P Real-world evidence of ribociclib induced liver toxicity in patients with breast cancer: A multi-center experience
Authors: O. Bas, B.K. Inci, I. Eroglu, S.C. Efil, S. Kaya, P. Kubilay Tolunay, C. Karacin, O. Yazici, M.A.N. Sendur, B.O. Oksuzoglu, S. Aksoy
Journal: Annals of Oncology (2024)
1920P Multiomics analysis of malignant pleural mesothelioma and the effect of immune checkpoint inhibitors
Authors: A.T. Tateishi, T. Yoshida, K. Shiraish, M. Torasawa, Y. Igawa, K. Masuda, Y. Shinno, Y. Okuma, Y. Goto, H. Horinouchi, N. Yamamoto, T. Kohno, Y. Ohe
Journal: Annals of Oncology (2024)
1884P Development and validation of a prediction tool for severe treatment-related toxicities in older cancer patients on systemic treatment (TR-TRM)
Authors: W.W.L. Chan, H. Hou, C.W.H. Choi, S.L.T. Yik, P.C.N. Tse, H.F.M. Cheng, W.L. Tsoi, T.K. Wu, L.S.J. Au, R. Liu, S. Siu, E. Cheung, C.L. Chiang, A. El-Helali, K.M. Cheung, K.C.R. Ngan, K.K. Yuen, D.L.W. Kwong, V.H.F. Lee
Journal: Annals of Oncology (2024)
1894P Pulmonary function test (PFT) and circulating biomarkers in immune-related pneumonitis (irP) in advanced non-small cell lung cancer (aNSCLC): A real-world multidisciplinary experience
Authors: L.C. Bao, F.M. Pontoriero, D. Pascale, F. Scalvenzi, C. Mulargiu, A. Ferro, A. Dal Maso, S. Frega, G. Pasello, D. Biondini, V. Guarneri, M. Tinè, L. Bonanno
Journal: Annals of Oncology (2024)
1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: Preliminary results from the TOMBOLA trial
Authors: J. Bjerggaard Jensen, K. Birkenkamp-Demtröder, I. Nordentoft, R.V. Milling, S.K. Körner, S.B. Brandt, M. Knudsen, G.W. Lam, L.H. Dohn, K. Fabrin, A. Carus, A. Petersen, U.N. Joensen, H. Pappot, P.S. Holt, N.V. Jensen, M. Agerbæk, L. Dyrskjot
Journal: Annals of Oncology (2024)
1911P Implementation of remote patient monitoring in thoracic oncology: A real-world experience from 489 pts across 41 centers in France
Authors: L. Greillier, B. Besse, H. Pegliasco, S. Deshayes, J-M. Vernejoux, D. Leite Ferreira, C. Tissot, B. Huret, M. Autheman, C. Parisi, M. Delaunay, J. Mazieres
Journal: Annals of Oncology (2024)
1979P Disitamab vedotin (DV) plus toripalimab (T) in unresectable locally advanced or metastatic urothelial carcinoma (la/mUC): Long-term outcomes from a phase Ib/II study
Authors: L. Zhou, K. Yang, S. Zhang, X. Yan, S. Li, H. Xu, J. Li, Z. Chi, L. Mao, B. Lian, T. Bixia, X. Wang, H. Guo, Z. He, J. Guo, X. Sheng
Journal: Annals of Oncology (2024)
1877P Adverse effects (AEs) of trastuzumab deruxtecan (T-DXd) in solid tumours: A meta-analysis
Authors: N. Pathak, M.R. Di Iorio, J. Savill, Y. Berner Wygoda, D. Malon Gimenez, M. Li, C. Molto Valiente, M. Nadler, A. Mittal, E. Amir
Journal: Annals of Oncology (2024)
1849P Clinical predictors of long-term responses to immune checkpoint inhibitors (ICI) in a multi-tumor cohort
Authors: V. Albarrán Fernández, P. Guerrero, C. Gonzalez Merino, C. García de Quevedo Suero, J. Chamorro-Perez, D.I. Rosero Rodriguez, A.M. Barrill Corpa, P. Sotoca-Rubio, V. Alia Navarro, P. Pérez de Aguado, J.C. Calvo, J. Moreno, M.V. San Roman Gil, P. Alvarez Ballesteros, A. Cortes Salgado, M.E. Olmedo Garcia, A. Gomez Rueda, P. Garrido Lopez, A. Soria Rivas, P. Gajate
Journal: Annals of Oncology (2024)
1974P A phase II trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder
Authors: G.J. DeCastro, M. Stein, C. Abate-Shen, C. Miles, J. Gray, B. Joffe, C. Anderson, A. Lenis, J.M.M. McKiernan
Journal: Annals of Oncology (2024)
1886P Expectations and priorities of older patients with cancer: The PRIORITY multicenter cohort study
Authors: T. Grellety, C. Bellera, C. Cantarel, C. Mertens, M. Cabart, G. Roubaud, M-C. Chantecaille, H. Desclos, A. Lefort, P. Bouchaert, E. Bourbouloux, C. Terret, C. Delattre, L. Cany, C. Lalet, S. Mathoulin, P. Soubeyran, C. Chakiba Brugere
Journal: Annals of Oncology (2024)
1897P Time to access to diagnosis and treatment for lung cancer (LC): Experience within an Italian comprehensive cancer center
Authors: S. Nardin, L. Barcellini, G. Sacco, M. Ferrante, B.R. Pollone, L. Lucente, M.M. Latocca, C. Dellepiane, G. Rossi, E. Bennicelli, G. Barletta, L. Zinoli, E. Cella, S. Coco, S. Santamaria, S. Marconi, M. Tagliamento, M. Lambertini, L. Del Mastro, C. Genova
Journal: Annals of Oncology (2024)
1889P Addressing unmet needs in the management of persistent severe cancer pain: European expert recommendations
Authors: M. di Palma, M. Brown, M.L. Padilla, C. Hoefing, S. Bagchi, T. Macarulla Mercade, M. Iorfida, X. Zuidema, D. Dupoiron, A. Falcon Gonzalez, D. van Keulen, R. Kortbaoui, V. Guardamagna, C. Tornero, C. Perruchoud
Journal: Annals of Oncology (2024)
1937P Clinical characteristics and prognosis of pediatric patients with papillary thyroid carcinoma
Authors: J. Akaishi, K. Sugino, R. Katho, Y. Kuga, A. Matsui, R. Ohara, K. Yoshioka, Y. Saito, C. Masaki, K.Y. Hames, R. Okamura, C. Tomoda, A. Suzuki, K. Matsuzu, W. Kitagawa, M. Nagahama, K. Ito
Journal: Annals of Oncology (2024)
1919P Clinical actionability of germline alterations in pleural mesothelioma: Results from a multicentric study
Authors: L. Cerbone, M. Sculco, A. Aspesi, M. La Vecchia, S. Delfanti, A.M. De Angelis, C. Bertolina, F. Marengo, F. fuligni, A. Cimorelli, I. Dianzani, F. Grosso
Journal: Annals of Oncology (2024)
1923P Real-world management and outcome of thymic carcinomas in a tertiary German center
Authors: A. Margineanu, M. Blasi, M. Hamilton, F. Bozorgmehr, M. Eichhorn, R. Rieker, M. Schneider, T. Muley, F. Weykamp, M. Allgäuer, H. Bischoff, A. Stenzinger, H. Winter, H. Grosch, M. Thomas, P. Christopoulos
Journal: Annals of Oncology (2024)
1930P Resensitization of BRAF-mutated radioactive iodine refractory differentiated thyroid cancer with longer duration of dabrafenib and trametinib
Authors: J.J. Niu, K. Milas, A. Edmond, M. Camou, C. Tomeh, T. Shellenberger, R. Metzger, J. Nelson, I. Ahmad, C. Nasr
Journal: Annals of Oncology (2024)
1964MO Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution
Authors: A.B. Apolo, K. Ballman, G.P. Sonpavde, S. Berg, W. Kim, R. Parikh, M.Y. Teo, R.F. Sweis, D. Geynisman, P. Grivas, G. Chatta, Z. Reichert, J.W. Kim, M.A. Bilen, B.A. McGregor, S. Srinivas, S. Halabi, G. Perez Burbano, M.J. Morris, J.E. Rosenberg
Journal: Annals of Oncology (2024)
1981P Cabozantinib plus durvalumab in patients with advanced and chemotherapy-treated urothelial carcinoma (UC) and variant histology (VH): An open-label, phase II, single-arm proof-of-concept trial: ARCADIA study. Subgroup analysis for bone metastasis
Authors: M. Stellato, P. Giannatempo, A. Polymeropoulos, V. Guadalupi, M. Claps, P. Ambrosini, D. Raggi, A. Rametta, C. Cavalli, E. Gusmaroli, C. Ortega, M. Tucci, S. Buti, S. Pipitone, R. Iacovelli, G. Calareso, A. Alessi, G. Procopio, R. Miceli, A. Necchi
Journal: Annals of Oncology (2024)
1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
Authors: M.D. Galsky, V.S. Koshkin, M.T. Campbell, A. Drakaki, I. Bowman, A.A.N. Rose, J.R. Brown, J.B. Aragon-Ching, S. Gadde, A. Harandi, J.E. Rosenberg, N. Matsubara, K.M. Sokolowski, M. Ichimaru, S. Chan, S. Franco, T.B. Powles
Journal: Annals of Oncology (2024)
1940TiP Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design
Authors: A. Garcia Alvarez, B. Castelo Fernández, C. López, J. Martínez-Trufero, T. Alonso-Gordoa, A. Carmona-Bayonas, G. Marquin, N. Martínez-Lago, P. Jimenez-Fonseca, M. Plana Serrahima, E. Grande, J. Hernando, J. Capdevila Castillon
Journal: Annals of Oncology (2024)
1864P Study on the real-life use of G-CSF in patients with lung cancer: Secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG
Authors: D. Debieuvre, L. Falchero, D. Templement Grangerat, S. Larive, A. Belle, L. Belmont, A. Mairovitz, J. Letreut, C. Delmas, K. Menia
Journal: Annals of Oncology (2024)
1867P Efficacy of lower dose of dexamethasone premedication in patient receiving docetaxel-based chemotherapy in preventing hypersensitivity reaction: A randomized controlled trial
Authors: S. Chanmaniloet, C. Vinayanuwattikun, N. Parinyanitikul, N. Zungsontiporn, N. Teeyapun, S. Tanasanvimon, S. Mingmalairak, N. Pakvisal, T. Susiriwatananont, N. Poovorawan, P. Sitthideatphaiboon
Journal: Annals of Oncology (2024)
1950P Squamous cell carcinoma of unknown primary (SCCUP): A genomic landscape study
Authors: H.R. Robinson, S. Lakritz, D.C. Pavlick, S.L. Davis, C. Lieu, C. Eule, L.S. Graham, P. Spiess, R. Li, A. Kamat, P. Grivas, J.M. Jacob, G. Bratslavsky, A. Basnet, K. Wong, K. Murugesan, D.I. Lin, A. Necchi, J.S. Ross, E.T. Lam
Journal: Annals of Oncology (2024)
1936P Treatment outcomes of patients with anaplastic thyroid carcinoma (atc): Multicentric data from spanish national registry (regetne-tiroides)
Authors: J.M. Rodellar, J. Hernando Cubero, A. Garcia Alvarez, I. Ceballos Lenza, M. Plana Serrahima, E. Gallardo, M.R. Bella, P. Jimenez Fonseca, C. Lopez, R. Jimeno Mate, N. Martinez Lago, P. Ayala de Miguel, J. Molina Cerrillo, A.R. Granados, C. Gonzalez Merino, M. Viana Aragonés, G. González Martín, J. Capdevila Castillon, T. Alonso Gordoa
Journal: Annals of Oncology (2024)